Gilead Sciences | GILD - Trade Creditors

Stock Price
149.37
Daily Change
3.14 2.15%
Monthly
23.08%
Yearly
52.36%
Q1 Forecast
137.58

Gilead Sciences reported $808M in Trade Creditors for its fiscal quarter ending in September of 2025.





Trade Creditors Change Date
AbbVie USD 32.25B 1.2B Jun/2025
Agios Pharmaceuticals USD 19.55M 2.02M Sep/2025
ALKERMES USD 68M 31.21M Sep/2025
Alnylam Pharmaceuticals USD 117.59M 15.2M Sep/2025
Amgen USD 19.64B 1.61B Sep/2025
Biogen USD 432M 18.9M Dec/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Bristol-Myers Squibb USD 4.29B 1.14B Sep/2025
Eli Lilly USD 4.26B 186.5M Sep/2025
Gilead Sciences USD 808M 226M Sep/2025
GlaxoSmithKline GBP 15.38B 294M Dec/2025
Glaxosmithkline GBP 21.07B 7.42B Sep/2025
Incyte USD 171.92M 1.24B Sep/2025
J&J USD 9.62B 161M Sep/2025
Merck USD 4.15B 102M Sep/2025
Moderna USD 267M 92M Sep/2025
Neurocrine Biosciences USD 119.9M 15.3M Sep/2025
Novartis USD 4.56B 49M Sep/2025
Pfizer USD 5.02B 142M Sep/2025
PTC Therapeutics USD 36.62M 169.69M Sep/2025
Regeneron Pharmaceuticals USD 5.83B 4.93B Dec/2025
Sanofi EUR 22.93B 927M Dec/2025
Sarepta Therapeutics USD 94.02M 42.69M Sep/2025
United Therapeutics USD 468M 36M Sep/2025
Vertex Pharmaceuticals USD 4.03B 320.8M Sep/2025